VolitionRx Ltd. (NYSE American: VNRX) provided a consolidated update on its clinical and commercial progress across key platforms, including a new cancer detection method with an estimated annualized total addressable market opportunity of approximately $23 billion. The company submitted a manuscript for peer review showcasing both a new method, Capture-Seq, and new biomarkers for the detection of cancer.
Commercialization of the Nu.Q Cancer assay advanced in lung cancer, with the company reporting that its reimbursement submission in France is on track, and routine clinical use is expected by Q4 2026. Volition also confirmed inclusion of its Nu.Q NETs assay in the $7.3 million government-backed DETECSEPS program in France for early detection of sepsis. Additionally, the company highlighted new clinical utility data for its assay in Hidradenitis Suppurativa, noting CE-marked availability across Europe.
In the veterinary sector, Volition reported breakthrough results demonstrating 100% specificity in detecting feline lymphoma using its Nu.Q Vet Feline assay. The company stated that publication of the feline study is expected to unlock a $5 million contractual milestone payment. Volition also confirmed ongoing licensing discussions with approximately 10 global diagnostic leaders and anticipates announcing additional licensing agreements during 2026.
For more details, the full press release is available at https://ibn.fm/rgAob. Volition is a multi-national epigenetics company dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection and monitoring.
